Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells which help in immunity, as well as kinases that play key roles in various cancers.
The international, multicenter, randomized, double-blind, controlled, phase 3 study intends to evaluate the efficacy and safety of masitinib in combination with bortezomib (Velcode®) and dexamethasone as compared with that of a placebo.
Nearly 300 patients will be enrolled across 75 centers around the world.
The primary response evaluation will be the Overall Progression Free Survival progression free survival (PFS).